# name
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain

# metadata.dc.description.abstract[].value
Objective: to estimate the health and economic impact of the reduction in mortality and cardiovascular hospitalizations, associated with correct diagnosis of cardiac transthyretin amyloidosis (ATTR-CM), from the Spanish National Health System (NHS) perspective. Methods: a costs and effects analysis were performed (probabilistic Markov model) with time horizons between 1 and 15 years, comparing the correct diagnosis of ATTR-CM versus the non-diagnosis. Transition probabilities were obtained from the ATTR-ACT study (placebo arm) and from the literature. Costs and healthcare resources were obtained from Spanish sources (  2019) and from a panel of Spanish clinical experts. Results: after 1, 5, 10 and 15 years, the diagnosis of ATTR-CM would generate a gain of 0.031 (95%CI 0.025; 0.038); 0.387 (95%CI 0.329; 0.435); 0.754 (95%CI 0.678; 0.781) and 0.944 (95%CI 0.905; 0.983) life years per patient, respectively, with savings of   212 (95%CI   -632; 633),   2,289 (95%CI   2,250; 2,517),   2,859 (95%CI   2,584; 3,149) and   2,906 (95%CI   2,669; 3,450) per patient, respectively, versus the non-diagnosis. Conclusions: just by correctly diagnosing ATTR-CM, years of life would be gained, cardiovascular hospitalizations would be avoided, and savings would be generated for the NHS, compared to the non-diagnosis of the disease.

# metadata.dc.relation.ispartof[].value
Expert Review of Pharmacoeconomics & Outcomes Research, 2011, vol. 11, p. 1-7

# metadata.dc.rights[].value
cc by nc nd (c) Formiga Pérez, Francesc et al, 2011

# metadata.dc.source[].value
Articles publicats en revistes (Ciències Clíniques)

# metadata.dc.title[].value
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain